Abstract
We recommend that Doptelet not be reimbursed by public drug plans for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP). Evidence from 1 clinical trial showed that Doptelet improved patients’ platelet counts after 6 months of treatment; however, it is not known whether Doptelet can reduce bleeding occurrence, reduce the use of other therapies for ITP used concomitantly with Doptelet, improve symptoms, or improve health-related quality of life when compared to placebo. In addition, evidence from 1 indirect treatment comparison study showed that the comparative efficacy of Doptelet to other established treatments for chronic ITP remains unknown. Patients identified a need for treatments that can reduce the risk of bleeding and improve their quality of life. However, there was not enough evidence to show that Doptelet would meet this need.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
